DermBiont, Inc.
- Biotech or pharma, therapeutic R&D
DermBiont is advancing two phase-2b/3 ready targeted, topical small molecules in the clinic:
SM-020 (kinase inhibitor) for the prevention of BCC in subjects with Gorlin Syndrome
SM-030 (PKCβ inhibitor) for the treatment of melasma
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}